One typically associates speech-language therapists with the quest to restore or improve the ability to talk. My favorite ...

In a worldwide first, a one-and-done gene therapy has been approved to treat a form of hereditary deafness. Many of the ...

A national trial to explore the benefits of giving deaf adults double cochlear implants could be "utterly life changing", according to a former opera singer. Janine Roebuck hid her deteriorating ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the pediatric participants. However, Deaf community advocates worry about the p ...

The ASX company said it expected underlying annual profit to fall between $290m and $330m. Previously, Cochlear had guided to a profit of between $435m and $460m and had then indicated profits would ...

Hearing implant maker Cochlear on Wednesday cut is earnings guidance by about 23.5 per cent to between $290m and $330m for the 2026 financial year. Investors were told that tough trading conditions ...

The world’s gone cold on treating hearing loss and Australia’s Cochlear is bearing the brunt. Cochlear isn’t selling hearing implants like it thought it could or should. It’s been a problem throughout ...

Cochlear’s chief executive Dig Howitt has alarmed investors with a shock earnings downgrade only two months after the hearing devices giant had published its forecast profit, blaming soft sales for ...

Slashes FY26 earnings view sharply below consensus Flags soft trading conditions in developed markets Warns of impact from strong Australian dollar Shares end 40.7% lower in worst session ever April ...

SYDNEY--Cochlear shares are on course for their worst day since the hearing-implant maker went public in 1995, tumbling 40% after the Australian company slashed its annual profit guidance on weak U.S.

Cochlear reduces its FY26 earnings guidance amid softer implant sales, ongoing challenges in key markets, and a focus on long-term growth. You’re reading a free article with opinions that may differ ...